Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Jonathan Trent"'
Autor:
Leticia Campoverde, Felipe Camacho, Francesco Alessandrino, Mark G. Evans, Andrew Elliot, Andrew Rosenberg, Jonathan Trent
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Soft tissue sarcomas harboring EWSR1::CREM fusion are rare and challenging to treat. Pazopanib, a multi-tyrosine kinase inhibitor, is FDA-approved for advanced soft tissue sarcomas, but predictive biomarkers for its efficacy remain unidentified. We c
Externí odkaz:
https://doaj.org/article/9ed53ca6d2434d72a0d38833d166622a
Autor:
Ignacio Garrido-Laguna, Asaf Maoz, Wungki Park, Abdul Rafeh Naqash, Vaia Florou, Breelyn Wilky, Jonathan Trent, Umang Swami, Garrett Frampton, Heloisa P Soares, Sonam Puri, Aik Choon Tan, Charalampos S Floudas, Carter Norton, Ethan S Sokol, Peter Hosein, Gilberto de Lima Lopes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background Pembrolizumab is FDA approved for tumors with tumor mutational burden (TMB) of ≥10 mutations/megabase (mut/Mb). However, the response to immune checkpoint inhibitors (ICI) varies significantly among cancer histologies. We describe the la
Externí odkaz:
https://doaj.org/article/206cd2d9903d405d9e63f577bd3f9aea
Autor:
Jia Lu, Ting Li, Zhichao Liao, Hui Yu, Yongtian Zhao, Haixiao Wu, Zhiwu Ren, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Xiangchun Li, Kexin Chen, Jonathan Trent, Jilong Yang
Publikováno v:
Cancer Biology & Medicine, Vol 19, Iss 6, Pp 910-930 (2022)
Objective: Sarcomas are a group of rare malignancies with various subtypes. Patients with metastatic sarcoma who have failed traditional treatments can possibly achieve better prognoses from using novel therapies, including anti-programmed death-1 (P
Externí odkaz:
https://doaj.org/article/c9d8bb2d69d6402e9d300785d035cfea
Autor:
James C. H. Yang, Marcia S. Brose, Gilberto Castro, Edward S. Kim, Ulrik N. Lassen, Serge Leyvraz, Alberto Pappo, Fernando López-Ríos, John A. Reeves, Marc Fellous, Frédérique Penault-Llorca, Erin R. Rudzinski, Ghazaleh Tabatabai, Gilles Vassal, Alexander Drilon, Jonathan Trent
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors. Larotrectinib is a first-in-class, highly sel
Externí odkaz:
https://doaj.org/article/d03b60bd6de0450a90283154c262afe5
Autor:
Matthieu Roulleaux Dugage, Robin Lewis Jones, Jonathan Trent, Stéphane Champiat, Sarah Dumont
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Gastrointestinal stromal tumors (GISTs) are a subtype of soft tissue sarcoma (STS), and have become a concept of oncogenic addiction and targeted therapies.The large majority of these tumors develop after a mutation in KIT or platelet derived growth
Externí odkaz:
https://doaj.org/article/34d21e319981407b956b19f4327ac42e
Autor:
Hong Zhang, Robert Wesolowski, Cesar Perez, Breelyn Wilky, Waldo Ortuzar Feliu, Remigiusz Kaleta, Jonathan Trent
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d9efd596b15243f99e0eff9a0bab8841
Autor:
Shaina Sedighim, Jonathan Burke, Douglas Schneider, Talia Kamdjou, Julio A. Diaz-Perez, Jonathan Trent, Mecker Möller
Publikováno v:
Gynecologic Oncology Reports, Vol 33, Iss , Pp 100592- (2020)
CIC-rearranged round cell sarcoma (CRS) is a rare entity that presents in various anatomical locations and involves deep soft-tissue structures and skin. Although commonly confused with and clinically similar to Ewing sarcoma (ES), investigators have
Externí odkaz:
https://doaj.org/article/9e08b2d2a3e34a1597979987b3225e02
Publikováno v:
European Journal of Surgical Oncology. 49:1133-1139
Retroperitoneal soft tissue sarcomas mainly consist histologically of liposarcomas and leiomyosarcomas. For the liposarcoma subgroup, the local relapse rate seems to determine patients' overall prognosis. In contrast, leiomyosarcoma patients are chal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbefb67f82acd636ee9b5a811b17cf83
https://doi.org/10.1016/j.ejso.2021.12.465
https://doi.org/10.1016/j.ejso.2021.12.465
Autor:
Jerry Call, Jonathan Wojtkowiak, Denisse Evans, Pete Knox, Thomas J. Hughes, Maeven Luedke, Sahibjeet Kaur, Carolyn Tordella, Mary Garland, Paul T. Lim, Norman J. Scherzer, Sara Rothschild, Jonathan Trent
Publikováno v:
Cancer Investigation. :1-13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c113cfddd834cd62cae4e723856f5408
https://doi.org/10.1080/07357907.2023.2201629
https://doi.org/10.1080/07357907.2023.2201629
Autor:
Steven Bialick, Leticia Campoverde, Jesus Antonio Ocejo Gallegos, Priscila Barreto-Coelho, Aleksandra Watson, Kshitij Arora, Andres Perez, Esdras Lopez, Shree Venkat, Andrew E. Rosenberg, Brooke Crawford, Emily Jonczak, Jonathan Trent, Aditi Dhir, Gina D’Amato
Publikováno v:
Current Treatment Options in Oncology. 24:528-541
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb550889242d5ac4b97647b621110e21
https://doi.org/10.1007/s11864-023-01073-4
https://doi.org/10.1007/s11864-023-01073-4